PATENT CLAIM ANALYSIS

Application Number: 15892295
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "044000"]

Abstract:
Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

Claim (Index 88):
A method of treating cancer in a patient in need thereof, the method comprising delivering a therapeutically effective amount of a retroviral vector particle of  claim 83 , followed by administration of a nucleoside analogue or a prodrug thereof to the patient in need thereof.

Metadata:
- Claim Count in Document: 83.0
- Percentile: 88.0
- Lexical Diversity: 1.275
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14214522', '14214448', '15516012', '10457604', '15211586']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7172679566694898
- 35 USC 102 Novelty (BERT): 0.7016840777527632
- Combined Prediction Score: 0.7157095687778172
- Mean Citation Score: 426.671468
- Max Citation Score: 831.2875
- Similarity Product: 693.4796246491372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test